Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab

Rheumatology International

Volumn 22, Issue 6, 2002, Pages 227-232

  Cauza, Edmund ^a   Spak, Marita ^a   Cauza, Karla ^b   Hanusch Enserer, Ursula ^a   Dunky, Attila ^a   Wagner, Ernst ^a  

^a Wilhelminenspital ^*  (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Infliximab; Psoriasis vulgaris; Psoriatic arthritis; Tumor necrosis factor

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG EFFECT; HOSPITALIZATION; IMMUNOLOGY; JOINT; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PSORIASIS; SKIN;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036431775     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-002-0246-3     Document Type: Article

References (41)

1. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 36:1681-1690
2. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
3. Szekanecz Z, Koch AE, Kunkel SL, Strieter RM (1998) Cytokines in rheumatoid arthritis: Potential targets for pharmacological intervention. Drugs Aging 12:377-390
4. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-602
6. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF α monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 7:251-259
7. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor (alpha) monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
8. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNFα by iv infusion of a chimeric monoclonal TNFα antibody in patients with rheumatoid arthritis: Short term cellular and molecular effects. J Immunol 156:1646-1653
9. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H (1994) Randomised double blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110
10. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in a patient with rheumatoid arthritis. Lancet 344:1125-1127
11. Gladmann DD (1994) Natural history of psoriatic arthritis. In: Wright V, Helliwell P (eds) Psoriatic Arthritis. Bailliere's Clinical Rheumatology International Practice and Research, vol 8. Bailliere Tindall, London, p 379
12. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis - Analysis of 220 patients. QJM 62:127
13. Gomez-Vaquero C, Rodriguez-Moreno J, Ros S, Marcos R, Fiter J, Roig-Escofet D (1996) Termination of disease-modifying drugs in psoriatic arthritis: Study of 109 courses of treatment. Br J Rheumatol 35:564-567
14. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT (1995) Long term methotrexate therapy in psoriatic arthritis. Clinical and radiologic outcome. J Rheumatol 22:241
15. Wolfe F, Cathey MA (1991) The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 18:1298-1306
16. Wolfe F, Hawley DJ, Cathey MA (1990) Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17:994-1002
17. Morand EF, McCloud PI, Littlejohn GO (1992) Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 19:704-708
18. McKendry RJR, Dale P (1993) Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 20:1850-1856
19. Dechant C, Antoni C, Wendler J (2000) One year outcome of patients with severe psoriatic arthritis treated with infliximab. Arthritis Rheum 43[Suppl]:212
20. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 59:428-433
21. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M (2001) Treatment of psoriatic arthritis with anti tumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144:587-589
22. Braun J, Sieper J (2000) Anti-TNF alpha: A new dimension in the pharmacotherapy of the spondylarthropathies? Ann Rheum Dis 59:404-407
23. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E (2001) New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 13:245-249
24. Zabraniecki L, Fournie B (2001) TNF alpha inhibition in psoriatic arthritis: Cause for hope. Joint Bone Spine 68:106-108
25. De Keyser FD, Mielants H, Veys EM (2001) Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2:85-93
26. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 356:385-390
27. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS (1997) Highly increased levels of tumor necrosis factor a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518-523
28. Ackermann L, Harvima IT (1998) Mast cells of psoriatic and atopic dermatitis skin are positive for TNFα and their degranulation is associated with expression of ICAM1 in the epidermis. Arch Derm Res 290:353-359
29. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544-1552
30. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR (1994) Elevated tumor necrosis factor alpha and biological activity in psoriatic skin lesions. Clin Exp Immun 96:146-51
31. Gladman D, Farewell VT, Nadeau C (1995) Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model. J Rheumatol 22:675-679
32. Felson D, Anderson J, Lange M, Wells G, Lavalley M (1998) Should improvement in rheumatoid arthritis clinical trails be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41:1564-1571
33. Christophers E, Sterry W (1993) Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds) Dermatology in General Medicine. McGraw-Hill, New York, pp 489-515
34. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB (2000) Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43:1244-1256
35. Nishibu A, Han GW, Iwatsuki K, Matsui T, Inoue M, Akiba H, Kaneko R, Kaneko F (1999) Overexpression of monocyte-derived cytokines in active psoriasis: A relation to coexistent arthropathy. J Dermatol Sci 21:63-70
36. Elkayam O, Yaro I, Shirazi I, Yaron M, Caspi D (2000) Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 19:101-105
37. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen J (1998) Upregulation of cytokine receptors TNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 25:105-110
38. Moll JMH, Wright V (1973) Familial occurrence of psoriatic arthritis. Ann Rheum Dis 32:181-201
39. Pitzalis C, Pipitone N (2000) Psoriatic arthritis. J R Soc Med 93:412-415
40. Oh CJ, Das KM, Gottlieb AB (2000) Treatment with antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42:829-830
41. Van Deventer SJH (1997) Tumor necrosis factor and Crohn's disease. Gut 40:443-448